Avalo Therapeutics, Inc. (AVTX)
13.38
-0.52
(-3.74%)
USD |
NASDAQ |
Apr 15, 16:00
13.38
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (Annual) : 50.08M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 12.71M |
| AbbVie, Inc. | 8.249B |
| Relmada Therapeutics, Inc. | 26.88M |
| Theravance Biopharma, Inc. | 35.91M |
| Corcept Therapeutics, Inc. | 254.91M |